- Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis2016 | First Faculty of Medicine, Second Faculty of Medicine
- Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease2020 | Faculty of Medicine in Hradec Králové
- Assessment of mucosal healing during biological therapy of small bowel Crohn’s disease by capsule endoscopy: a prospective observational study2013 | First Faculty of Medicine
- Mucosal healing is not associated with better outcome during 7 years of follow-up in pediatric patients with Crohn's disease2023 | Faculty of Medicine in Hradec Králové
- Can we change the prognosis for patients with Crohn's disease? : comments of the results of the EXTEND trial2011 | First Faculty of Medicine
- Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease2012 | First Faculty of Medicine
- Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort2018 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Outcomes of long-term maintenance infliximab therapy in adult patients with moderate to severe Crohn's disease from March 2003 to December 2010: A single centre experience2012 | Faculty of Mathematics and Physics
- Present and future of Crohn's disease treatment2013 | First Faculty of Medicine
- The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease2019 | Second Faculty of Medicine
- Faecal bacteriome and metabolome profiles associated with decreased mucosal inflammatory activity upon anti-TNF therapy in paediatric Crohn's disease2024 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Does golimumab extend the spectrum of anti-TNFalpha inhibitors for inflammatory bowel diseases?2012 | First Faculty of Medicine
- Biological therapy of inflammatory bowel diseases with adalimumab2019 | First Faculty of Medicine
- Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study2015 | First Faculty of Medicine
- Histopathological assessment of the intensity and activity of the inflammation in inflammatory bowel diseases: An important addition to the endoscopy, or a pointless effort?2019 | Second Faculty of Medicine
- Single-balloon enteroscopy in patients with Crohn's disease - single centre's experience2011 | First Faculty of Medicine
- The efficacy and safety of budesonide MMX (Cortiment(R)) for long-term maintenance therapy of ulcerative colitis2018 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Budesonide MMX (Cortiment(R) 9 mg) in the treatment of ulcerative colitis in real clinical practice2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN2017 | Second Faculty of Medicine
- Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II2021 | Faculty of Medicine in Hradec Králové
- Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 - results from clinical practice2020 | First Faculty of Medicine
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial2017 | First Faculty of Medicine, Central Library of Charles University